Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study

被引：24

作者：

Valle, JW

Dangoor, A

Beech, J

Sherlock, DJ

Lee, SM

Scarffe, JH

Swindell, R

Ranson, M

机构：

[1] Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England

[2] N Manchester Grp Hosp, Pennine Acute Hosp NHS Trust, Manchester M8 5RB, Lancs, England

[3] Middlesex Hosp, London W1T 3AA, England

[4] Lister Hosp, E&N Herts NHS Trust, Stevenage SG1 4AB, Herts, England

来源：

BRITISH JOURNAL OF CANCER | 2005年 / 92卷 / 04期

关键词：

pegylated liposomal doxorubicin; hepatocellular carcinoma; phase II;

D O I：

10.1038/sj.bjc.6602394

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Monthly intravenous pegylated liposomal doxorubicin (PLD) 50 mg m(-2), although well tolerated, showed almost no activity in this phase II study of 16 patients with advanced hepatocellular carcinoma with a response rate of 0%, stable disease 19%, median time to progression of 2.4 months, 1-year survival of 25% and median survival of 6.5 months.

引用

页码：628 / 630

页数：3

共 50 条

[1] Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study
J W Valle
A Dangoor
J Beech
D J Sherlock
S M Lee
J H Scarffe
R Swindell
M Ranson
British Journal of Cancer, 2005, 92 : 628 - 630
[2] A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma
Halm, U
Etzrodt, G
Schiefke, I
Schmidt, F
Witzigmann, H
Mössner, J
Berr, F
ANNALS OF ONCOLOGY, 2000, 11 (01) : 113 - 114
[3] Pegylated liposomal doxorubicin (PLD) and gemcitabine (G) in the treatment of advanced hepatocellular carcinoma (HCC)
Pastorelli, D.
Zustovich, F.
Lombardi, G.
Zovato, S.
Farina, M.
Furini, L.
Faggioni, G.
Nicoletto, M. O.
Ceravolo, R.
EJC SUPPLEMENTS, 2009, 7 (02): : 395 - 396
[4] Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: A phase II study
Di Lorenzo, Giuseppe
Rea, Antonio
Carlomagno, Chiara
Pepe, Stefano
Palmieri, Giovannella
Labianca, Roberto
Chirianni, Antonio
De Stefano, Alfonso
Esposito, Vincenzo
De Placido, Sabino
Montesarchio, Vincenzo
WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (48) : 6553 - 6557
[5] A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma
Ruey-Long Hong
Yun-Long Tseng
Cancer Chemotherapy and Pharmacology, 2003, 51 : 433 - 438
[6] A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma
Hong, RL
Tseng, YL
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 51 (05) : 433 - 438
[7] Phase II study of pegylated liposomal doxorubicin (Caelyx) in advanced hepatocellular carcinoma (HHC).
Ruff, P
Moodley, SD
Rapoport, BL
Chasen, MR
Jacobs, C
Hacking, D
Voroblof, DA
ANNALS OF ONCOLOGY, 2000, 11 : 69 - 70
[8] Gemcitabine (GEM) and pegylated liposomal doxorubicin (PLD) in recurrent metastatic breast carcinoma: A phase II study
Ferrandina, G.
Adamo, V.
Ferrau, F.
Condemi, G.
Di Lullo, L.
Rossello, R.
Lorusso, D.
Garipoli, C.
Scambia, G.
ANNALS OF ONCOLOGY, 2005, 16 : 18 - 18
[9] Pegylated Liposomal Doxorubicin and Gemcitabine in Patients With Advanced Hepatocellular Carcinoma Results of a Phase 2 Study
Lombardi, Giuseppe
Zustovich, Fable
Farinati, Fabio
Cillo, Umberto
Vitale, Alessandro
Zanus, Giacomo
Donach, Martin
Farina, Miriam
Zovato, Stefania
Pastorelli, Davide
CANCER, 2011, 117 (01) : 125 - 133
[10] Activity and safety of pegylated liposomal doxorubicin,5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma:A phase Ⅱ study
Giuseppe Di Lorenzo
Antonio Rea
Chiara Carlomagno
Stefano Pepe
Giovannella Palmieri
Roberto Labianca
Antonio Chirianni
Alfonso De Stefano
Vincenzo Esposito
Sabino De Placido
Vincenzo Montesarchio
World Journal of Gastroenterology, 2007, (48) : 6553 - 6557

← 1 2 3 4 5 →